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Systematic review of long term effects of advice to reduce
dietary salt in adults
Lee Hooper, Christopher Bartlett, George Davey Smith, Shah Ebrahim
Abstract
Objective To assess the long term effects of advice to
restrict dietary sodium in adults with and without
hypertension.
Design Systematic review and meta›analysis of
randomised controlled trials.
Data sources Cochrane library, Medline, Embase, and
bibliographies.
Study selection Unconfounded randomised trials
that aimed to reduce sodium intake in healthy adults
over at least 6 months. Inclusion decisions, validity
and data extraction were duplicated. Random effects
meta›analysis, subgrouping, sensitivity analysis, and
meta›regression were performed.
Outcomes Mortality, cardiovascular events, blood
pressure, urinary sodium excretion, quality of life, and
use of antihypertensive drugs.
Results Three trials in normotensive people
(n=2326), five trials in those with untreated
hypertension (n=387), and three trials in people being
treated for hypertension (n=801) were included, with
follow up from six months to seven years. The large
high quality (and therefore most informative) studies
used intensive behavioural interventions. Deaths and
cardiovascular events were inconsistently defined and
reported. There were 17 deaths, equally distributed
between intervention and control groups. Systolic and
diastolic blood pressures were reduced (systolic by 1.1
mm Hg, 95% confidence interval 1.8 to 0.4 mm Hg;
diastolic by 0.6 mm Hg, 1.5 to − 0.3 mm Hg) at 13 to
60 months, as was urinary 24 hour sodium excretion
(by 35.5 mmol/24 hours, 47.2 to 23.9). Degree of
reduction in sodium intake and change in blood
pressure were not related.
Conclusions Intensive interventions, unsuited to
primary care or population prevention programmes,
provide only small reductions in blood pressure and
sodium excretion, and effects on deaths and
cardiovascular events are unclear. Advice to reduce
sodium intake may help people on antihypertensive
drugs to stop their medication while maintaining
good blood pressure control.
Introduction
Several systematic reviews have reported that restrict›
ing sodium intake in people with hypertension reduces
their blood pressure.1–5 However, most of the trials in
these systematic reviews were short term and did not
allow for complete adjustment of blood pressure to
altered sodium intake or reduced motivation for
following dietary restrictions over time. Also, some
trials increased sodium intake in one arm and
compared this with a reduced sodium intake in the
other arm and so did not estimate likely effects of cut›
ting down on sodium in a normal diet.6 7 No review on
long term outcomes has been carried out since 1998,7
although large relevant trials have been published.
The value of lowering blood pressure depends on
its effects on cardiovascular events and deaths. The
published systematic reviews on the effect of salt
restriction on blood pressure and other risk factors
have disagreed about the size of blood pressure
changes8 and the effects on cardiovascular events and
deaths. We assessed, in people with and without hyper›
tension, the efficacy of advice to reduce dietary sodium
intake over at least six months on mortality, cardiovas›
cular events, blood pressure, urinary sodium excretion,
quality of life, and use of antihypertensive medications.
Methods
A previous large scale search for dietary trials and
cardiovascular disease covered the Cochrane library,
Medline, Embase, CAB abstracts, CVRCT registry, and
SIGLE to May 1998 plus bibliographies of collected
papers and reviews.9 We carried out a further search,
seeking trials on sodium restriction and blood pressure
in Medline, Embase, and the Cochrane library (to July
2000). We checked bibliographies of systematic reviews
and included trials; the searches were not limited by
language.
We included trials in which randomisation was
adequate, there was a usual or control diet group, the
intervention aimed to reduce sodium intake, the inter›
vention was not multifactorial, the participants were
not children, acutely ill, pregnant, or institutionalised,
follow up was at least 26 weeks, and data on any of the
review outcomes were available.
For this review our primary outcomes were
mortality and cardiovascular events, blood pressure,
and urinary sodium excretion. We also collected data
on quality of life and use of antihypertensive
medication.
Two authors (LH and CB) assessed inclusion and
validity and carried out data extraction independently
in duplicate. Any differences were resolved by
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discussion and, when necessary, by a third reviewer
(SE). For assessment of quality we collected data on
randomisation procedure, allocation concealment,
blinding of participants, providers of care, outcome
assessors, and losses to follow up.10
For urinary sodium excretion and blood pressure
we collected data on mean (SD) change from baseline
for intervention and control groups at intermediate
(latest data point from 6 to 12 months), late (13 to 60
months), and very late (after 60 months) follow up.
Four trials provided baseline and follow up values, with
SD or SE, but no SD for the change from baseline.11–14
We used three studies in which data were provided at
baseline and follow up and mean differences given15–17
to calculate values for the correlations between
baseline and follow up (for the control and experimen›
tal groups for systolic and diastolic blood pressure
values but not for urinary sodium excretion).18 We used
a conservative estimate (lowest correlation) to compute
the SD of mean changes for four studies without this
data. Correlations varied from − 5.79 to 0.56.
In factorial trials of calorie and sodium reduction
we used only data from the sodium reduction and con›
trol groups because, of three such factorial trials,17 19 20
two showed definite17 or probable19 interaction effects.
In one trial data on urinary sodium excretion were not
available for sodium reduction groups alone but event
and medication data were available and were used in
analyses.20 Calorie reduction and calories plus sodium
reduction arms were included in a sensitivity analysis.
We attempted to contact authors of all included
trials for further information on trial characteristics,
quality, and outcomes (including number and type of
cardiovascular events, deaths, quality of life assess›
ments, urinary sodium excretion, intake of other nutri›
ents, blood pressure, and weight) as well as information
on further published or unpublished trials.
Two trials were cluster randomised. In one small
trial 19 general practitioners were randomised to
deliver simple advice on low salt diets or no such advice
to 77 patients.13 Patient numbers in the intervention
and control groups were reduced to an effective
sample size as described by Hauck,21 assuming the
intraclass correlation (appropriate for nonfamilial
clusters such as randomised practice units) to be 0.5.22
The other cluster randomised trial individually
randomised “index” men and women and then
included members of their families in the trial.23 We
used only the “index” participants in our meta›analysis.
We checked the meta›analyses (weighted mean dif›
ferences, random effects model, on Cochrane Collabo›
ration Review Manager 4.1 software) for heterogeneity
by visual inspection and by Cochran’s test. We used
sensitivity analysis to assess the robustness of the
results to exclusion of the data with estimated SDs, or
use of the largest correlations to estimate these SDs,
exclusion of trials with unknown or inadequate alloca›
tion concealment, and addition of weight reduction
arms.10 24 We used the STATA metareg command25 for
random effects meta›regression.26 We did not use
funnel plots to investigate the presence of publication
bias because the number of trials in each group was
too small.
We used subgrouping of trials and meta›regression
to examine the effects on blood pressure of length of
follow up on sodium excretion and blood pressure, ini›
tial systolic blood pressure, presence or absence of
hypertension, age, and change in sodium excretion.
Results
Study characteristics
Figure 1 shows details of exclusion and inclusion of
studies. Table 1 shows the characteristics of the 11 trials
included.
We included three trials in people without
hypertension (n=2326),16 17 19 five in people with
untreated hypertension (n=387),11 13 15 23 27 and three in
people with treated hypertension (n=801),12 14 20 with
follow up from six months to seven years. The people
without hypertension were healthy (predominantly
white men, mean age 40 years) with high normal blood
pressure. The people with untreated hypertension
were aged 16 to 64 years, while those with treated
hypertension were aged 55 to 67 years. In trials on
people with hypertension, sex and ethnic characteris›
tics were generally poorly documented. All the trials in
people without hypertension, but only one trial in
people with treated hypertension,20 used a comprehen›
sive behavioural change programme, whereas the oth›
ers used varying types of advice or leaflets.
The quality of the trials, as judged by concealment
of allocation, seemed higher in the trials in people
without hypertension. Other aspects of quality that we
assessed included blinding of outcome assessment and
losses to follow up (table 1). There were different meth›
ods of dealing with missing data associated with losses
to follow up. Most trials attempted to blind outcome
assessors.
Potentially relevant publications
identified and screened
for retrieval (n=18 689)
Papers retrieved for more
detailed evaluation (n=218)
Papers excluded on basis of title
and abstract (generally due to lack
of suitability of study design or
intervention) (n=18 471)
Studies included in systematic
review, but with no usable data
on events, blood pressure, sodium
excretion, or medication (n=1)
Papers coalesced into studies
(further publications of single
studies grouped) (n=25)
Papers included (n=36)
Included studies (with or
without appropriate
outcome data (n=11)
Excluded
Non-randomised
Lack of 6 month follow up
No appropriate control
Multifactorial intervention
No useful outcomes
Children
(n=23)
(n=62)
(n=8)
(n=50)
(n=1)
(n=1)
Studies with outcome data useful
in the systematic review (n=10)
By outcome:
Mortality
Morbidity
Blood pressure
Sodium excretion
Quality of life
Antihypertensive medication
(n=4)
(n=4)
(n=7)
(n=6)
(n=3)
(n=2)
Fig 1 Flow diagram of systematic review (QUOROM statement flow
diagram)
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Mortality and cardiovascular events
Mortality and cardiovascular events were inconsistently
reported. No differences in periods of admission to
hospital were seen between intervention groups in the
hypertension prevention trial (no further data were
provided).19 Morgan et al reported that three
participants in the control group and two participants
on low sodium diets were treated for cardiac failure,
with four cardiovascular deaths in the low sodium
group and two in the control group.15 28 The trial of
non›pharmacological interventions in elderly people
recorded a wide range of cardiovascular events: 57 in
control participants and 44 in those on low sodium
diets (relative risk 0.77, 95% confidence interval 0.41 to
1.14).20 29 However, only nine of these events were due
to stroke or myocardial infarction. Overall, the trials
Table 1 Characteristics of trials of sodium restriction included in meta›analysis
Trial name Participants Intervention Control Outcomes Quality
People without hypertension
HPT 1990 (USA)19 Mean age 39 years, 62%
men, 84% white, DBP 78›89
mm Hg, not on AHTM
196 assigned to dietary and
behavioural change programme;
174 followed up at 6 months,
175 at 36 months; target USE
<70
196 assigned to no dietary
counselling; 191 followed up
at 6 months, 178 at 36
months
BP and USE at 0, 6, 36
months, % on
antihypertensive drugs
Allocation adequately concealed;
participants not blinded; outcome
assessors blinded; participants
with no follow up excluded;
others given reading from last
visit (or treated BP if higher)
TOHP phase I 1992
(USA)16
Mean age 43 years, 71%
male, 77% white, DBP 80 to
89 mm Hg, not on AHTM
327 assigned to group nutrition
and behavioural counselling
programme; 301 followed up at
12 months, 304 at 18 months;
target USE 80
417 assigned to no
intervention; 392 analysed at
12 months, 395 at 18 months
BP and USE at 0, 6, 12, 18
months
Allocation adequately concealed;
participants not blinded; outcome
assessors blinded; participants
with no follow up reading taken
as zero change, others given
reading from last visit
TOHP phase II 1997
(USA)17
Mean age 44 years, 67%
male, 81% white, DBP 83 to
89 mm Hg, SBP <140 mm
Hg, not on AHTM
594 assigned to dietary and
behavioural change programme,
intensive early on, contact
maintained later; 529 followed up
at 6 months, 515 at 36 months;
target USE 70
596 assigned to no active
intervention; 538 analysed at
6 months, 514 at 36 months
BP and USE at 0, 6, 18, 36
months (42 or 48 months
sometimes)
Allocation adequately concealed
participants not blinded
outcome assessors blinded;
participants with no follow up
reading given random value from
range of results, others given
reading from last visit
People with untreated hypertension
Morgan 1978
(Australia)15 28
>50 years, all men, DBP
95›109 mm Hg, no AHTM
34 for BP (35 for mortality)
assigned to instruction to reduce
their dietary sodium chloride
intake; 26 followed up at 24
months (all followed for
mortality); target sodium intake
70›100 mmol/24 hours
33 for BP (42 for mortality)
assigned to no dietary
treatment; 21 followed up at
24 months (all followed for
mortality)
BP and USE at 0, 6, 12, 18,
24 months
Concealment of allocation
unclear; participants not blinded;
outcome assessors blinded;
participants with no follow up
excluded, reading at last visit
used for remainder
Costa 1981 (Italy)11 Age range 16›31 years,
“untreated borderline
hypertension”
21 assigned to receive low salt
diet; 20 followed up; target 3 g
NaCl/day
20 advised on diet with
unrestricted salt; 21 [sic]
followed up
BP and intralymphocytic
sodium at 0 and 12 months
Concealment of allocation
unclear; participants not blinded;
unclear if outcome assessors
blinded; adjustment for losses
not specified
Thaler 1982 (New
Zealand)23
Mean age 41 years, 48%
male, index subjects: SBP
137›180 mm Hg, 21% on
AHTM (family members also
included)
80 (38 index + 42 family)
assigned to salt restriction
programme for whole family; 69
followed up at 8 months; USE
target not stated
84 (39 index + 45 family)
asked to eat usual diet, 67
followed up at 8 months
USE at 0 and 8 months Concealment of allocation
unclear; participants not blinded;
unclear if outcome assessors
blinded; losses excluded
Silman 1983 (UK)27 Aged 50 to 64, DBP 95›104
mm Hg
12 assigned to general health
education group package with
spouses plus taught about low
salt diet; 10 followed up at 12
months; USE target 100
16 assigned to general health
education group package
only; 15 followed up at 12
months
BP and USE at 0, 1, 2, 3, 6,
12 months
Concealment of allocation
unclear; participants not blinded;
unclear if outcome assessors
blinded; losses excluded;
baseline readings for “excluded”
compared with those for
“included”
Alli 1992 (Italy)13 Mean age 48 years, 42%
men, BMI<30, DBP 90›104
mm Hg, not on AHTM
40 assigned (by GP
randomisation) to receive low
sodium dietary advice; 26
followed up at 12 months; USE
target <80
37 assigned (by GP
randomisation) to maintain
usual diet; 30 followed up at
12 months
BP and USE at 1, 3, 6, 9, 12
months
Allocation inadequately concealed
(cluster randomisation by GP);
participants not blinded;
assessors not blinded; losses
excluded
People with treated hypertension
Morgan 1987
(Australia)14
Mean age 61 years, all men,
DBP <85 mm Hg on AHTM
(>100 uncontrolled)
10 assigned to low sodium diet;
10 followed up at 9 months;
target sodium intake 50›75
mmol/24 hours
10 assigned to maintained
normal diet; 10 followed up at
9 months
Necessity to restart AHTM
after withdrawal, USE at 0 and
9 months
Concealment of allocation
unclear; participants not blinded;
outcome assessors blinded; last
BP reading before reinstatement
was used; all had at least one
follow up
Arroll 1995 (New
Zealand)12
Mean age 55 years, 52%
men, on AHTM (DBP >70 to
105 mm Hg or SBP >155 to
180 mm Hg)
51 asked to reduce use of high
salt foods, salt added at table
and in cooking; 44 followed up
at 6 months; USE targets not
stated
49 assigned to no
intervention; 43 followed up at
6 months
BP and AHTM levels after
withdrawal of AHTM at 0 and
6 months, USE at 6 months
Concealment of allocation
unclear; participants not blinded;
outcome assessors blinded;
losses excluded from BP
measurement, no adjustment
made for those who decreased
or stopped medication
TONE 1998 (USA)20 Mean age 67 years, 49%
men, 76% white, on AHTM,
DBP <85 mm Hg, SBP <145
mm Hg
340 assigned to group plus
individual nutrition and
behavioural counselling
programme; 310 followed up at
30 months; USE target <80
341 assigned to no
counselling; 314 followed up
at 30 months
Combined BP, use of AHTM,
and cardiovascular events.
USE at 0, 9, 18, 30 months
Allocation adequately concealed;
participants not blinded; outcome
assessors blinded; used survival
analysis with censoring to project
proportions free of end points
AHTM=antihypertensive medication, SBP=systolic blood pressure, DBP=diastolic blood pressure, USE = urinary sodium excretion, in mmol/ 24 hours, GP=general practitioner.
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reported few deaths: nine in control groups and eight
in low sodium groups.
Blood pressure
Table 2 shows changes in blood pressure and urinary
sodium excretion for each trial, and table 3 shows
pooled changes at intermediate and late assessments
(fig 2). Reductions in systolic and diastolic blood pres›
sure were apparent at both intermediate (2.5 mm Hg,
3.8 to 1.2; 1.2 mm Hg, 1.8 to 0.7, respectively) and late
follow up (1.1 mm Hg, 1.8 to 0.4; 0.6 mm Hg, 1.5 to
− 0.3). When we carried out sensitivity analyses exclud›
ing low quality trials, which included all trials on
people with untreated hypertension, the statistical
heterogeneity that had been apparent for systolic
blood pressure at intermediate follow up and diastolic
blood pressure at late follow up was no longer
apparent. As these trials were small the effect on
pooled estimates of change in blood pressure was
minor. Sensitivity analyses including all arms of the
factorial trials,17 19 suggest that inclusion of weight
reduction arms reduces the effect on blood pressure.
Meta›regression of change in blood pressure up to 12
months that used all trials with relevant data showed
Study
Change in systolic blood pressure
  Hypertension prevention trial 199019
  Morgan 197815
  Trials of hypertension (TOHP) I 199216
  Trials of hypertension (TOHP) II 199717
Subtotal (95% CI)
Test for heterogeneity c 2=2.57, df=3, P=0.46
Test for overall effect z=3.09, P=0.002
Change in diastolic blood pressure
  Hypertension prevention trial 199019
  Morgan 197815
  Trials of hypertension (TOHP) I 199216
  Trials of hypertension (TOHP) II 199717
Subtotal (95% CI)
Test for heterogeneity c 2=6.71, df=3, P=0.082
Test for overall effect z=1.31, P=0.19
No
Salt reduction
175
31
327
594
1127
175
31
327
594
1127
No
Control
178
31
417
596
1222
178
31
417
596
1222
-10 -5 0 5 10
Favours low salt Favours control
Mean
(SD)
-2.80 (9.20)
-5.50 (22.30)
-4.90 (7.80)
-0.70 (9.20)
-2.80 (6.60)
-5.00 (11.10)
-4.10 (5.70)
-2.90 (6.80)
Mean
(SD)
-2.90 (9.30)
-4.00 (22.30)
-3.20 (8.10)
0.30 (8.90)
-3.00 (6.70)
2.00 (11.10)
-3.30 (5.70)
-2.40 (7.10)
Weighted mean difference
(95% CI random)
Weighted mean difference
(95% CI random)
0.10 (-1.83 to 2.03)
-1.50 (-12.60 to 9.60)
-1.70 (-2.85 to -0.55)
-1.00 (-2.03 to 0.03)
-1.12 (-1.83 to -0.41)
0.20 (-1.19 to 1.59)
-7.00 (-12.53 to -1.47)
-0.80 (-1.63 to 0.03)
-0.50 (-1.29 to 0.29)
-0.61 (-1.54 to 0.31)
Fig 2 Change in systolic and diastolic blood pressure achieved in trials of 13 to 60 months (mm Hg)
Study
At 6 to 12 months
  Hypertension prevention trial 199019
  Sliman 198327
  Trials of hypertension (TOHP) I 199216
  Trials of hypertension (TOHP) II 199717
  TONE 199620
  Thaler (men) 198223
  Thaler (women) 198223
Subtotal (95% CI)
Test for heterogeneity c 2=22.55, df=6, P=0.001
Test for overall effect z=5.82, P=0.00001
At 13 to 60 months
  Hypertension prevention trial 199019
  Trials of hypertension (TOHP) I 199216
  Trials of hypertension (TOHP) II 199717
  TONE 199620
Subtotal (95% CI)
Test for heterogeneity c 2=8.31, df=3, P=0.04
Test for overall effect z=5.96, P=0.00001
Over 60 months
  Trials of hypertension (TOHP) I 199216
Subtotal (95% CI)
Test for heterogeneity c 2=0, df=0
Test for overall effect z=0.85, P=0.4
165
7
228
99
487
19
18
1023
143
232
470
487
1332
54
54
185
11
323
101
488
17
18
1143
155
330
482
488
1455
66
66
-100 -50 0 50 100
Favours salt reduction Favours control
-35.70 (63.50)
-26.40 (30.20)
-55.70 (76.10)
-78.00 (86.20)
-45.20 (132.00)
-64.90 (97.90)
-31.60 (55.10)
-16.00 (68.00)
-55.20 (76.90)
-50.90 (86.30)
-39.80 (143.00)
10.80(61.00)
-14.80 (67.20)
26.40 (39.80)
2.80 (80.30)
-27.60 (108.00)
1.40 (132.00)
49.30 (67.70)
8.40 (63.00)
0.00 (71.10)
-11.30 (77.70)
-10.50 (88.50)
-0.30 (132.00)
0.30(75.00)
Weighted mean difference
(95% CI random)
Weighted mean difference
(95% CI random)
-20.90 (-34.60 to -7.20)
-52.80 (-85.26 to -20.34)
-58.50 (-71.70 to -45.30)
-50.40 (-77.46 to -23.34)
-46.60 (-63.17 to -30.03)
-114.20 (-168.73 to -59.67)
-40.00 (-78.67 to -1.33)
-48.94 (-65.42 to -32.46)
-16.00 (-31.80 to -0.20)
-43.90 (-56.87 to -30.93)
-40.40 (-51.50 to -29.30)
-39.50 (-56.78 to -22.22)
-35.53 (-47.22 to -23.85)
10.50 (-13.83 to 34.83)
10.50 (-13.83 to 34.83)
No
Salt reduction
No
Control
Mean
(SD)
Mean
(SD)
Fig 3 Change in urinary sodium achieved in trials of 6 to 12 months, 13 to 60 months, and >60 months (mmol Na/24 hours)
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Table 2 Results of trials included in meta›analysis. Figures are mean (SD) for blood pressure (mm Hg) and urinary sodium excreted in 24 hours (mmol) for
control and interventions groups
Trial name
Initial
mean
systolic
BP
Change in
systolic BP at
latest point to 12
months
Change in systolic BP
at latest point after
12 months
Initial
mean
diastolic
BP
Change in diastolic
BP at latest point
to 12 months
Change in diastolic
BP at latest point
after 12 months
Initial
urinary
sodium
Change in urinary
sodium at latest
point to 12 months
Change in urinary
sodium at latest point
after 12 months
People without hypertension
HPT 1990
Control 123.9 −2.1 (8.3)* at 6
months
−2.9 (9.3)* at 36
months
83.0 −3.0 (6.9)* at 6
months
−3.0 (6.7)* at 36
months
164.9† −14.8 (67.2)† at 6
months
0.0 (71.1)† at 36
months
Intervention 124.0 −3.8 (7.9)* at 6
months
−2.8 (9.2)* at 36
months
82.6 −3.4 (6.6)* at 6
months
−2.8 (6.6)* at 36
months
162.6† −35.7 (63.5)† at 6
months
−16.0 (68.0)† at 36
months
TOHP phase I 1992
Control 125.1
(8.1)
−3.9 (7.4) at 12
months
−3.16 (8.1) at 18
months
83.9 (2.8) −3.4 (5.7) at 12
months
−3.3 (5.7) at 18
months
156.4 (60.5) 2.8 (80.3) at 6
months
−11.3 (77.7) at 18
months
Intervention 124.8
(8.5)
−5.8 (7.5) at 12
months
−4.9 (7.8) at 18
months
83.7 (2.7) −4.4 (5.4) at 12
months
−4.1 (5.7) at 18
months
154.6 (59.9) −55.7 (76.1) at 6
months
−55.2 (76.9) at 18
months
TOHP phase II 1997
Control 127.3
(6.4)
−2.2 (8.1) at 6
months
0.3 (8.9) at 36 months 85.8 (1.9) −2.8 (6.1) at 6
months
−2.4 (7.1) at 36
months
188.0 (80.9) −27.6 (108.0) at 6
months
−10.5 (88.5) at 36
months
Intervention 127.7
(6.6)
−5.1 (8.6) at 6
months
−0.7 (9.2) at 36
months
86.1 (1.9) −4.4 (6.7) at 6
months
›2.9 (6.8) at 36
months
186.1 (80.7) −78.0 (86.2) at 6
months
−50.9 (86.3) at 36
months
People with untreated hypertension
Morgan 1978
Control 165
(16.7)
−3 (22.3) at 12
months
−4 (22.3) at 24
months
97 (8.6) 1 (11.1) 2 (11.1) at 24
months
191 (35) Not given −11 at 24 months
Intervention 160
(22.3)
−3 (22.3) at 12
months
−5.5 (22.3) at 24
months
97 (8.7) ›3 (11.1) −5 (11.1) at 24
months
195 (55.0) −38 at 24 months
Costa 1981
Control 143.4
(13)
4.3 (18.8)‡ at 12
months
84.1 (7) −0.2 (32.6)‡ at 12
months
Not given Not given
Intervention 143.3
(15)
−14.0 (18.5)‡ at
12 months
84.2 (9) −6.1 (31.7)‡ at 12
months
Thaler 1982, index men
Control 139 (12) 3.4 (17.4)§ at 12
months
90 (12) 0.8 (9.2)§ at 12
months
159.5 (72.5) 49.3 (67.7) at 12
months
Intervention 137 (14) −5.0 (8.3)§ at 12
months
86 (9) 0.6 (9.2)§ at 12
months
178.1 (76.5) −64.9 (97.9) at 12
months
Thaler, index women
Control 148 (25) 1.1 (14.4)§ at 12
months
83 (12) 2.8 (8.5)§ at 12
months
120.1 (41.5) 8.4 (63.0) at 12
months
Intervention 145 (18) −11.1 (24.2)§ at
12 months
86 (11) −6.8 (11.9)§ at 12
months
118.0 (39.9) −31.6 (55.1) at 12
months
Silman 1983
Control 160.5 −20.0 (24.0) at
12 months
98.3 −11.4 (10.5) at 12
months
146.5 26.4 (39.8) at 12
months
Intervention 165.3 −28.7 (26.6) at
12 months
98.8 −17.7 (11.4) at 12
months
150.8 −26.4 (30.2) at 12
months
Alli 1992
Control 148.3
(10.6)
−0.3 (16.4)‡ at
12 months
97.2 (3.8) −2.7 (16.6)‡ at 12
months
177.3 (61.7) −4.2¶ at 12 months
Intervention 150.8
(8.7)
−6.6 (13.6)‡ at
12 months
97.0 (3.1) −6.4 (18.5)‡ at 12
months
177.3 (61.0) 8.6¶ at 12 months
People with treated hypertension
Morgan 1987
Control 143
(15.8)
35 (25.7)‡§ at 9
months
81 (6.3) 17 (28.7)‡§ 163 (50.6) −8
Intervention 143
(15.8)
12 (21.5)‡§ at 9
months
83 (6.3) 7 (22.2)‡§ 168 (37.9) −93
Arroll 1995
Control 145.3
(15.7)
−6.2 (21.0)‡§ at
6 months
94.0 (9.8) −4.8 (36.1)‡§ at 6
months
Not given Not given
Intervention 145.4
(15.9)
−9.1 (21.7)‡§ at
6 months
86.4 (9.9) −1.7 (34.9)‡§ at 6
months
TONE 1998
Control 128 (9) 71 (7) 146.2 1.4 (132)** at 9
months
−0.3 (132)** at 30
months
Intervention 129 (9) 72 (7) 145.3 −45.2 (132)** at 9
months
−39.8 (143)** at 30
months
*Change data adjusted for baseline differences in composition of treatment groups on 12 covariates
†8 hour overnight urine samples collected, means (SD) adjusted to 24 hour data (×3.8).
‡SD calculated as explained in methods.
§Levels of antihypertensive medications altered in some participants through study so data not used in meta›analyses.
¶Data measured off graph, so estimated.
**Data include urinary sodium data for those in weight loss group (added into control, total n=488) and weight loss plus sodium reduction group (added into intervention, total n=487) as this
information was not available for separate intervention groups.
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no relation with change in urinary sodium excretion,
baseline systolic blood pressure, or age (table 4).
Urinary sodium excretion
We found reductions in urinary 24 hour sodium excre›
tion at both intermediate (48.9 mmol/24 hours, 65.4 to
32.5) and late follow up (35.5 mmol/24 hours, 47.2 to
23.9) (fig 3). We identified significant heterogeneity in
both analyses that was not explained by trial quality.
One trial in people without hypertension found that at
seven years sodium excretion in a small subset of the
original sample was similar in intervention and control
groups.30
Quality of life
Information on quality of life was patchy, with no com›
mon outcome measures. The hypertension prevention
trial asked participants whether they were having
problems with their diets.31 Of those in the low sodium
group, 69% reported problems such as inconvenience
and difficulty with adherence when eating out at some
time during the three years of the trial, and problems
were reported at 42% of clinic visits.
The trials of hypertension prevention, phase I
(TOHP I), reported psychological wellbeing scores,
which improved significantly in participants in the low
sodium groups at 18 months compared with the non›
intervention control group.32 Thaler et al reported that
participants did not find it difficult to stop adding salt at
table, but many found cutting down on salt in cooking
harder.23 Most found their low salt bread (salt cut from
2.1% to 1.0% dry weight) and salt›free butter
acceptable. Only 13% of participants reported their
salt restricted diet as unpleasant or worse. Overall
dropout rates, a possible marker of quality of life on
trial, were similar (relative risk 1.04; 0.86 to 1.25) in low
sodium and control groups.
Antihypertensive medications used
Low salt diets seemed to allow people with
hypertension to stop taking medication. In one small
trial that compared 10 men in each group, six on low
sodium diets had not restarted antihypertensive drugs
at six months compared with only one in the control
group (relative risk 0.44; 0.20 to 0.98).14 In a larger
study of 975 participants, primary end points (a
combination of high blood pressure at any visit,
restarting antihypertensive medication, or any clinical
cardiovascular disease) were less common in the low
sodium group (relative risk 0.83, 0.75 to 0.92).20
Discussion
Eleven long term randomised controlled trials of
dietary salt reduction (including 3491 participants)
provided few data on mortality (17 deaths in total),
cardiovascular events, or quality of life but did show
significant falls in systolic blood pressure (1.1 mm Hg,
1.8 to 0.4) and urinary sodium excretion (35.5
mmol/24 hours, 47.2 to 23.9) at 13 to 60 months after
initial advice. Falls in diastolic blood pressure were
smaller and were consistent with no effect (0.6 mm Hg,
1.5 to − 0.3). A low salt diet may help people on
Table 3 Results of meta›analysis, subgrouping, and sensitivity analysis
Type of analysis
No of
studies
Weighted mean
difference (95% CI)
P value for
heterogeneity
Sodium excretion (mmol Na/24 hours)
Overall analysis (at 6 to 12 months) 6 −48.9 (−65.4 to −32.5) 0.001
Sensitivity analysis:
Allocation concealment 4 −43.6 (−62.6 to −24.6) 0.001
Including weight arms 6 −44.3 (−58.4 to −30.2) <0.001
Overall analysis (at 13 to 60 months) 4 −35.5 (−47.2 to −23.9) 0.04
Sensitivity analysis:
Allocation concealment 4 −35.5 (−47.2 to −23.9) 0.04
Including weight arms 4 −33.3 (−42.0 to −24.6) 0.05
Overall analysis (at >60 months) 1 10.5 (−13.8 to 34.8)
Systolic blood pressure (mm Hg)
Overall analysis (at 6 to 12 months) 7 −2.5 (−3.8 to −1.2) 0.08
Sensitivity analysis:
Drop calculated SD 5 −2.3 (−3.0 to −1.7) 0.57
Smallest calculated SD 7 −3.1 (−4.8 to −1.3) 0.01
Allocation concealment 3 −2.3 (−3.1 to −1.6) 0.31
Including weight arms 7 −1.6 (−3.0 to −0.2) <0.001
Subgroups:
No hypertension 3 −2.3 (−3.1 to −1.6) 0.31
Untreated hypertension 4 −8.0 (−15.8 to −0.2) 0.15
Overall analysis (at 13 to 60 months) 4 −1.1 (−1.8 to −0.4) 0.46
Sensitivity analysis:
Allocation concealment 3 −1.1 (−1.9 to −0.3) 0.28
Including weight arms 4 −0.5 (−1.4 to 0.4) 0.10
Subgroups:
No hypertension 3 −1.1 (−1.9 to −0.3) 0.28
Untreated hypertension 1 −1.5 (−12.6 to 9.6)
Overall analysis (at >60 months) 1 −3.8 (−7.9 to 0.3)
Diastolic blood pressure (mm Hg)
Overall analysis (at 6 to 12 months) 7 −1.2 (−1.8 to −0.7) 0.51
Sensitivity analysis:
Drop calculated SD 5 −1.2 (−1.8 to −0.6) 0.31
Smallest calculated SD 7 −1.3 (−2.1 to −0.6) 0.25
Allocation concealment 3 −1.2 (−1.8 to −0.6) 0.28
Including weight arms 7 −0.7 (−1.5 to 0.1) 0.05
Subgroups:
No hypertension 3 −1.2 (−1.8 to −0.6) 0.28
Untreated hypertension 4 −4.5 (−8.7 to −0.4) 0.97
Overall analysis (at 13 to 60 months) 4 −0.6 (−1.5 to 0.3) 0.08
Sensitivity analysis:
Allocation concealment 3 −0.5 (−1.1 to 0.0) 0.48
Including weight arms 4 −0.3 (−1.0 to 0.4) 0.06
Subgroups:
No hypertension 3 −0.5 (−1.1 to 0.0) 0.48
Untreated hypertension 1 −7.0 (−12.5 to −1.5)
Overall analysis (at >60 months) 1 −2.2 (−4.8 to 0.4)
Dropouts
Overall analysis in low sodium v control
groups (latest follow up)
10 RR=1.04 (0.86 to 1.25) 0.55
RR=relative risk.
Table 4 Meta›regression: effects of mean baseline systolic blood pressure, change in sodium excretion, mean age of participants on systolic blood pressure
at 6 to 12 months
Explanatory variable
Trials in people with and without hypertension Trials in people without hypertension
Slope coefficient (95% CI) Constant No of trials Slope coefficient (95% CI) Constant No of trials
Mean baseline systolic blood pressure −0.173 (−0.356 to 0.010) 19.5 7 −0.362 (−0.826 to 0.102) 43.3 3
Mean change in urinary sodium excretion
at 6›12 months
0.013 (−0.049 to 0.075) −1.68 4 0.013 (−0.057 to 0.084) −1.63 3
Mean age of participants at baseline 0.118 (−0.188 to 0.424) −7.46 7 −0.213 (−0.630 to 0.203) 6.81 3
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antihypertensive drugs to stop their medication
without loss of blood pressure control.
Limitations and strengths of review
Health promotion interventions involve several stages
before any health outcome is seen. Firstly, the advice
must result in changed behaviour (cutting down on salt
in food) and, secondly, that behaviour must result in an
improved health outcome (reduced cardiovascular
illness, increased life expectancy). A major limitation of
this review is that we were not able to assess the overall
effect of advice to reduce dietary sodium on mortality
or morbidity as too few events occurred. Instead we
assessed several intermediate outcomes including
urinary sodium excretion and blood pressure.
The observed sodium reduction of about a quarter
of usual intake in US and UK populations may be an
overestimate.33 Almost half the participants in one trial
ate differently on food record days, eating less food and
substituting simpler foods and also eating less salt.34
The completeness of urine samples is not known and it
has been suggested that less salty foods were eaten on
collection days in the trial of Thaler et al23 (O Simpson,
personal communication, 2001).
While both urinary sodium excretion and blood
pressure fell, the salt reduction may not have caused
the fall in blood pressure. Alterations in diet aimed at
reducing salt intake may systematically affect other
dietary components (such as alcohol, potassium, or
energy intake) that themselves alter blood pressure.
This might explain why we found no relation between
the degree of reduction in sodium excretion and
change in blood pressure. However, the number of
Table 5 Characteristics of systematic reviews on salt and blood pressure
Trial
Inclusion criteria
(population,
intervention, outcome,
design)
Only randomised
data included?
Normotensive
or
hypertensive
Median
(range)
duration of
trials
No of trials (No
of participants)
Fall in sodium
excretion
(mmol/24
hours)*
Pooled mean difference* (95%
CI) (mm Hg)
Quality assessment
and other detailSystolic BP Diastolic BP
Graudal
19984
Mean age >15 years;
low sodium or high
sodium diet, no
confounding; urinary
sodium excretion
measured, systolic,
diastolic or mean BP
reported
Yes, random
allocation,
parallel or
crossover
Normotensive 8 (4›1100)
days
56 (2581) 160 −1.2
(−0.6 to −1.8)
−0.26
(0.3 to −0.9)
Subgrouping by open/
single blind or double
blind method did not
affect results.
Statistical
heterogeneity noted
Hypertensive 28 (4›365)
days
58 (2161) 118 −3.9
(−3.0 to −4.8)
−1.9
(−1.3 to −2.5)
Midgley
19962
Not on antihypertensive
drugs; dietary sodium
intervention; diastolic
and systolic BP
measurement, urinary
sodium excretion;
English language, full
length journal articles
Yes, randomised
controlled trials
(crossover or
parallel design)
Normotensive 14 (4›1095)
days
28 (2374) 125
(95 to 156)
−1.6
(−2.41 to −0.89)
−0.5
(−1.18 to
0.11)
Significant
heterogeneity seen,
reduced but not
eliminated when
studies subgrouped
according to quality
characteristics.
Evidence of
publication bias
provided
Hypertensive 29 (4›730)
days
28 (1131) 95
(71 to 119)
−5.9
(−7.77 to −4.12)
−3.8
(−4.78 to
−2.9)
Law 19911† Not on antihypertensive
drugs; dietary sodium
restriction, not
confounded; 24 hour
urine collection, systolic
and/or diastolic BP
No Normotensive 1.5 (0.7 to 16)
weeks
15 (?) Not stated Not stated Not stated Quality not assessed.
Individual trial data
compared with pooled
observational data,
rather than pooled
together
Hypertensive 5 (0.7 to 104)
weeks
63 (?) Not stated Not stated Not stated
Cutler 19973 Adult; sodium goals
28›273 mmol/24 hours,
no confounding allowed;
lab›based measure of
sodium intake, systolic
and/or diastolic BP
measured
Yes, randomised
controlled trials
(crossover or
parallel design),
published only
Normotensive 1 (0.5 to 36)
months
12 (1689) Median z90
(range 16 to
210)
−1.5
(−2.1 to −1.0)
−0.8
(−1.3 to −0.3)
Subgrouping by
double blind or not
had no significant
effect on overall
outcome.
Regression analyses
used for publication
bias failed to reject
null hypothesis
Hypertensive 2 (1›24)
months
22 (1043) Median z71
(range 27 to
171)
−3.8
(−4.9 to −2.8)
−2.1
(−2.8 to −1.5)
Alam 19995 Aged >50 years;
changes in dietary NaCl;
blood pressure
Yes, published
English›language
randomised
controlled trials,
crossover or
parallel
Normotensive
(2 trials) or
with essential
hypertension
(9 trials)
14 (9›104)
weeks
11 (485) Median 80
(range 23 to
260)
−5.6
(−6.9 to −4.3)
−3.5
(−4.4 to −2.6)
Score tended to be
high (average score
>70%)
Ebrahim
and
Davey
Smith
19987
Adult; dietary sodium
reduction v control;
diastolic and systolic BP
measurement, urinary
sodium excretion
Yes, randomised
controlled trials
of at least 6
months duration
Normotensive Not stated 2 (1095) Not stated −1.3
(−2.7 to 0.1)
−0.8
(−1.8 to 0.2)
Quality not assessed
Hypertensive Not stated 6 (466) Not stated −2.9
(−5.8 to 0.0)
−2.1
(−4.0 to −0.1)
This review,
6›12
months
Adult; sodium reduced
diet v usual diet; urinary
sodium excretion,
systolic and/or diastolic
BP measurements taken
6 to 12 months or more
than 13 to 60 months
after intervention
Yes, parallel
randomised
controlled trials
Normotensive 6 (6 to 12)
months
3 (2326) 43
(16 to 70)
−2.3
(−3.1 to −1.6)
−1.2
(−1.8 to −0.6)
Sensitivity analysis
(removing trials
where allocation
concealment is poor
or unclear) had no
effect on direction or
significance of results
Hypertensive 12 (12 to 12)
months
4 (223) 48
(33 to 63)
−8.0
(−15.7 to −0.3)
−4.3
(−7.1 to −1.6)
This review,
13›60
months
Normotensive 36 (18 to 36)
months
3 (2326) 34
(19 to 50)
−1.1
(−1.9 to −0.3)
−0.5
(−1.1 to 0.0)
Hypertensive 24 months 1 (77) 40
(22 to 57)
−1.5
(−12.6 to 9.6)
−7.0
(−12.5 to
−1.5)
*Weighted mean (95% CI) unless stated otherwise. Weighting for all pooled data by inverse variance.
†Review estimates that in people aged 50›59 reduction in 50 mmol Na/24 hours would lead to reduction of 5 mm Hg in systolic and 2.5 mmHg in diastolic blood pressure in people without
hypertension and reduction of 7 mm Hg and 3.5 mm Hg, respectively, in people with hypertension.
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trials is small and relating a mean change in blood
pressure to a mean change in urinary sodium is statis›
tically weak. In previous meta›analyses an association
was seen in some cases but not others (table 5). Data on
individual participants are required to take this issue
further.
Despite the importance of answering the question
of the long term effects of dietary salt restriction, most
of the many randomised controlled trials published
have been of short duration and can show only that salt
restriction is capable of reducing blood pressure but
provide no useful information for primary care
practice. As randomised controlled trials are available,
we have not included population surveys, cohorts, or
animal trials that are unable to estimate the
unconfounded effects of salt restriction in human
populations and are difficult to interpret.35
Is it realistic to ask people to alter their salt intake
long term? Advice to reduce dietary salt is common in
primary care and is a central part of the guidelines
produced by the British Hypertension Society.36
Despite a great deal of ongoing encouragement and
support used in the trials included in this review, it
seems that salt reduction attenuates over time. In rou›
tine primary care the intervention is likely to be less
intense and therefore of more limited impact.
Comparison with previous studies
It is unclear what effects a low sodium diet has on
cardiovascular events and mortality. Lowering sodium
intake may have adverse effects on vascular endothe›
lium through stimulation of the renin›angiotensin sys›
tem37 and on serum total and low density lipoprotein
cholesterol concentrations.4 In cohort studies, lower
salt intake in people with hypertension has been asso›
ciated with higher levels of cardiovascular disease38 and
in general populations with greater all cause mor›
tality.39 40 However, among obese people lower salt
intake may be associated with a reduced risk of cardio›
vascular events.41 42 These apparently contradictory
findings may be explained by confounding or by
differential sensitivity to salt intake but make it less
clear that salt restriction is without hazards.
We expected that short duration trials would
achieve larger reductions in blood pressure that would
attenuate over time. As shown in table 5, short term
trials of median length of eight days showed a greater
reduction in urinary sodium excretion but a similar fall
in systolic blood pressure to the findings from long
term trials of median length 36 months in this review.
The recent dietary approaches to stop hypertension
(DASH) trial showed that over a 30 day period with
intensive measures, which included provision of all
food, systolic blood pressure can fall substantially (by
6.7 mm Hg, 5.4 to 8.0 mm Hg),43 but this finding is of
little relevance to the issue of achieving long term
reductions in blood pressure by practical means in pri›
mary care.
Implications
Long term maintenance of low sodium intake is
difficult, even with a great deal of support, advice, and
encouragement. A policy of reduction in salt intake for
the entire population through cutting salt concentra›
tions in processed foods,44 as recently announced by
the UK chief medical officer,45 can achieve small reduc›
tions in blood pressure across the whole population for
sustained periods of time. Individual reduction of risk
would be small, but across a whole population the
effects may be substantial.46 47
However, raised blood pressure is only one risk fac›
tor for cardiovascular disease and overall clinical
benefits (or harms) of a low sodium diet are unclear.
Revisiting all participants of the large trials in people
without hypertension some years later to assess long
term effects of low sodium dietary advice on mortality
and cardiovascular morbidity would be a cost effective
and relatively rapid way to assess the clinical effective›
ness of advice to reduce sodium intake. There is strong
justification for a large scale, long term randomised
controlled trial to explore the cost effectiveness of such
advice if it is to remain a part of the strategy for
prevention and treatment of hypertension.
Conclusions
On present evidence intensive interventions, unsuited
to primary care or population prevention pro›
grammes, produce uncertain effects on mortality and
cardiovascular events and only small reductions in
blood pressure. However, advice to reduce sodium
intake in the diet may help some people on antihyper›
tensive drugs to stop their medication while maintain›
ing good control of blood pressure.
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